Tue, Jul 22, 2014, 7:42 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

risingedge77 8 posts  |  Last Activity: Jun 24, 2014 3:27 PM Member since: Nov 4, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Will Lewis suggested that $50k to $100k for 6 months of treatment was possible.

    Sentiment: Buy

  • risingedge77 risingedge77 Jun 17, 2014 6:44 PM Flag

    Long time posters know that Premacure, not Therapure, was sold the rights to IPLEX to treat complications of prematurity, not "full rights".

    Sentiment: Buy

  • Reply to

    Partners by end of June

    by lux19insm May 21, 2014 10:48 PM
    risingedge77 risingedge77 May 21, 2014 11:24 PM Flag

    I think that he said that he would have answers from the FDA and EMA on the path(s) forward by the end of June.

    Sentiment: Buy

  • so that the filing can include the NTM indication in addition to Pa/CF. As Will Lewis said earlier, the Pa/CF filing in Europe would be in the second quarter of this year, unless the NTM results were good enough to make it a combined filing, and in that case it would be filed in second half of this year.

    Sentiment: Buy

  • While discussing slide 15, Resourcing for Success / Launch / Commercialization, Clinical Studies to Expand Label, Will Lewis said that "drug resistant TB is an example".

    Sentiment: Buy

  • risingedge77 risingedge77 Apr 24, 2014 12:47 PM Flag

    Maybe they mention it at one of the ATS Conference sessions.

    Sentiment: Buy

  • Reply to

    Joshua Schimmer from Piper Jaffray

    by insmhistorian Apr 23, 2014 7:22 PM
    risingedge77 risingedge77 Apr 23, 2014 7:25 PM Flag

    From the Piper Jaffray website:

    Joshua Schimmer, MD
    Sr Research Analyst

    Josh Schimmer is a managing director and senior research analyst who joined Piper Jaffray in 2013 to cover biotechnology companies. Schimmer has been on the Street for more than 10 years; prior to joining Piper Jaffray, he worked in equity research at Lazard Capital Markets, Leerink Swann and Cowen and Company. In addition, he spent time on the buy side at Davidson Kempner as part of the healthcare investing team. Schimmer holds a Doctor of Medicine (MD) from the University of Toronto, where he specialized in Internal Medicine and sub-specialized in Rheumatology. He also holds an MBA from Harvard Business School.

    Sentiment: Strong Buy

  • Insmed Shares Rally Over $14 as Piper Jaffray Boosts Price Target to $51
    Paul Quintaro, Benzinga Staff Writer

    Shares of Insmed (NASDAQ: INSM) spiked nearly 5 percent higher in mid-day trade Wednesday afternoon following some bullish comments from Piper Jaffray's Dr. Joshua Schimmer. The stock is now up more than 3 percent to around $14.49.

    Schimmer boosted his price target on Insmed shares by about 13 percent from $45 to $51. The analyst maintains an Overweight rating on Insmed.

    Schimmer cited the company's overall long-term strategy and tax structure, as well as upcoming opportunities for Arikayce in the Japanese market. The Piper analyst is optimistic about Insmed's current initiative to explore avenues to shift intellectual property to a lower tax region.

    Amid concerns a potentially brief Phase 3 trial will be needed in order to receive FDA approval for Arikayce in nontuberculous mycobacterial, Schimmer believes new opportunities for Insmed will more than offset conservative estimates.

    Based on the price of Insmed shares Wednesday afternoon, Schimmer's new price target implies potential upside of a jaw-dropping 250 percent.

    Sentiment: Strong Buy

INSM
17.70-0.04(-0.23%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.